Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

CancerVax, Serono partner for Canvaxin development

Executive Summary

CancerVax (cancer therapeutics) and Serono SA have entered into an agreement to further develop CancerVax's Canvaxin, a Phase III immunotherapeutic to treat advanced-stage melanoma.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Equity
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register